Q1 2026 Gland Pharma Ltd Earnings Call Transcript
Key Points
- Gland Pharma Ltd (NSE:GLAND) reported a 7% year-over-year growth in consolidated revenue for Q1 FY26, reaching INR15,056 million.
- The company's consolidated EBITDA increased by 39% year-over-year, with a margin improvement from 19% to 24%.
- Cenexi, a subsidiary of Gland Pharma Ltd, achieved breakeven EBITDA, marking a significant turnaround.
- The company successfully launched 9 new products in the US market during the quarter, contributing to its growth.
- Gland Pharma Ltd is expanding its capacity for pen and cartridge production from 40 million to 140 million units, with completion expected by March 2026.
- The rest of the world market saw only a modest 5% increase in revenue, indicating slower growth in some regions.
- The Indian market contributed only 4% to the total revenue, highlighting limited growth in the domestic market.
- Cenexi's performance, while improved, still faces challenges with full-year profitability not yet achieved.
- The US business experienced a decline in revenue growth due to timing issues and supply chain constraints.
- The company faces ongoing uncertainties around tariffs, which could impact future profitability and market dynamics.
Ladies and gentlemen, good day, and welcome to Gland Pharma Limited Q1 FY26 earnings conference call.
(Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Ms. Runjhun Jain. Thank you, and over to you, mam.
Thank you, Sagar. Good evening, everyone. Today, we have Mr. Srinivas Sadu, Executive Chairman; Mr. Shyamakant Giri, Chief Executive Officer; Mr. Ravi Mitra, Chief Financial Officer from India Office; and Mr. Alan, CEO of Cenexi, who's connected virtually.
Before we proceed, I would like to remind everyone that certain statements made today are forward-looking and based on management's current estimates. We should be considered in the context of risks inherent to our business. Please note that this call is being recorded, and a playback transcript will be available on our website shortly. With that, I hand over the call to Mr. Sadu for his opening remarks. Over to you, sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
